Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:3070 |
Name | high grade glioma |
Definition | A cell type cancer that has_material_basis_in glial cells and is located in brain or located in spine. |
Source | DiseaseOntology.org |
Alt Ids | DOID:2627 |
Path | disease disease of cellular proliferation cancer cell type cancer high grade glioma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
IDH1 R132C | AGI-5198 | high grade glioma | sensitive | detail... |
IDH1 R132H | AGI-5198 | high grade glioma | sensitive | detail... |
HRAS G12V | SF1126 | high grade glioma | sensitive | detail... |
IDH1 mutant | N/A | high grade glioma | not applicable | detail... |
ATRX loss IDH1 mut | Gemcitabine + Radiotherapy | high grade glioma | predicted - sensitive | detail... |
BRAF V600E | Everolimus + Selumetinib | high grade glioma | predicted - sensitive | detail... |
BRAF V600E | PLX4720 + Selumetinib | high grade glioma | predicted - sensitive | detail... |
BRAF V600E | Everolimus + PLX4720 | high grade glioma | predicted - sensitive | detail... |
BRAF wild-type | Everolimus + Selumetinib | high grade glioma | predicted - sensitive | detail... |
IDH1 R132H | BPTES | high grade glioma | sensitive | detail... |
IDH1 R132H | Talazoparib | high grade glioma | sensitive | detail... |
IDH1 R132C | Talazoparib | high grade glioma | sensitive | detail... |
IDH2 R140Q | AG-881 | high grade glioma | predicted - sensitive | detail... |
IDH1 R132H | AG-881 | high grade glioma | predicted - sensitive | detail... |
IDH2 mutant | N/A | high grade glioma | not applicable | detail... |
IDH1 R132H | N/A | high grade glioma | not applicable | detail... |
IDH1 wild-type | N/A | high grade glioma | not applicable | detail... |
IDH2 wild-type | N/A | high grade glioma | not applicable | detail... |
ATRX mutant | N/A | high grade glioma | not applicable | detail... |
BRAF V600E | Vemurafenib | high grade glioma | sensitive | detail... |
ATRX S458* | Adavosertib | high grade glioma | sensitive | detail... |
ATRX R781* | Adavosertib | high grade glioma | sensitive | detail... |
PIK3CA R88Q | Buparlisib + Selumetinib | high grade glioma | sensitive | detail... |
PIK3CA E542K | Buparlisib + Selumetinib | high grade glioma | sensitive | detail... |
PIK3CA H1047R | Buparlisib + Selumetinib | high grade glioma | sensitive | detail... |
HRAS mut PIK3CA M1043V | Buparlisib + Selumetinib | high grade glioma | sensitive | detail... |
HRAS mut PIK3CA R88Q | Buparlisib + Selumetinib | high grade glioma | sensitive | detail... |
HRAS mut PIK3CA E542K | Buparlisib + Selumetinib | high grade glioma | sensitive | detail... |
IDH1 mutant | AG-881 | high grade glioma | predicted - sensitive | detail... |
IDH2 mutant | AG-881 | high grade glioma | predicted - sensitive | detail... |
IDH1 R132H | Olaparib | high grade glioma | predicted - sensitive | detail... |
TP53 wild-type | AZ32 + Radiotherapy | high grade glioma | predicted - sensitive | detail... |
TP53 C238S | AZ32 + Radiotherapy | high grade glioma | sensitive | detail... |
TP53 R175H | AZ32 + Radiotherapy | high grade glioma | sensitive | detail... |
TP53 M237I | AZ32 + Radiotherapy | high grade glioma | sensitive | detail... |
TP53 dec exp | AZ32 + Radiotherapy | high grade glioma | sensitive | detail... |
TP53 mutant | AZ32 + Radiotherapy | high grade glioma | predicted - sensitive | detail... |
TP53 D281G | AZ32 + Radiotherapy | high grade glioma | sensitive | detail... |
TP53 mutant | AZ31 + Radiotherapy | high grade glioma | no benefit | detail... |
TP53 M237I | KU-60019 + Radiotherapy | high grade glioma | sensitive | detail... |
TP53 mutant | KU-60019 + Radiotherapy | high grade glioma | predicted - sensitive | detail... |
IDH1 mutant | Durvalumab + Olaparib | high grade glioma | no benefit | detail... |
ATRX loss | Talazoparib | high grade glioma | predicted - sensitive | detail... |
ATRX loss | Olaparib | high grade glioma | predicted - sensitive | detail... |
ATRX loss IDH1 R132H | Talazoparib | high grade glioma | predicted - sensitive | detail... |
ATRX loss IDH1 R132H | Olaparib | high grade glioma | predicted - sensitive | detail... |
ATRX loss | Ceralasertib + Olaparib | high grade glioma | predicted - sensitive | detail... |
BRAF V600E TET2 V1199E | Vemurafenib | high grade glioma | resistant | detail... |
BRAF V600E CBL dec exp | Vemurafenib | high grade glioma | predicted - resistant | detail... |
BRAF V600E CBL dec exp | Cobimetinib | high grade glioma | predicted - resistant | detail... |
BRAF V600E CBL dec exp | Neratinib | high grade glioma | predicted - resistant | detail... |
BRAF V600E | LY3009120 | high grade glioma | predicted - sensitive | detail... |
BRAF V600E | LY3009120 + Vemurafenib | high grade glioma | sensitive | detail... |
BRAF V600E | Belvarafenib | high grade glioma | predicted - sensitive | detail... |
BRAF V600E | ZM336372 | high grade glioma | no benefit | detail... |
BRAF V600E | Vemurafenib + ZM336372 | high grade glioma | predicted - sensitive | detail... |
BRAF V600E | Dabrafenib + Trametinib | high grade glioma | sensitive | detail... |
IDH2 R172K | TQ05310 | high grade glioma | sensitive | detail... |
IDH2 R140Q | TQ05310 | high grade glioma | sensitive | detail... |
FGFR1 K656E | Infigratinib | high grade glioma | predicted - sensitive | detail... |
FGFR3 K650E | Infigratinib | high grade glioma | predicted - sensitive | detail... |
BRAF fusion | Ulixertinib | high grade glioma | predicted - sensitive | detail... |
IDH1 R132H | Olaparib + Radiotherapy | high grade glioma | sensitive | detail... |
IDH1 mutant | Olaparib + Radiotherapy | high grade glioma | sensitive | detail... |
IDH1 mutant | Radiotherapy + Veliparib | high grade glioma | sensitive | detail... |
IDH1 R132H | Radiotherapy + Veliparib | high grade glioma | sensitive | detail... |
IDH1 R132H | Pamiparib + Radiotherapy | high grade glioma | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00602667 | Phase I | Cisplatin + Cyclophosphamide + Methotrexate + Vincristine Sulfate Cyclophosphamide + Etoposide + Topotecan Cyclophosphamide + Erlotinib + Topotecan | Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma | Active, not recruiting | USA | AUS | 0 |
NCT00876993 | Phase I | Bevacizumab + Irinotecan + Temozolomide | Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors | Completed | USA | 0 |
NCT00879437 | Phase II | Bevacizumab Valproic acid | Valproic Acid and Radiation Followed by Maintenance Valproic Acid and Bevacizumab in Children With High Grade Gliomas | Completed | USA | 0 |
NCT01052363 | Phase I | Bevacizumab + Fosbretabulin | OXC401-PO1s/WVU 1309 - A Pilot Study of Fosbretabulin With Bevacizumab in Recurrent High-Grade Gliomas | Withdrawn | USA | 0 |
NCT01089101 | Phase Ib/II | Selumetinib | Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma | Active, not recruiting | USA | 0 |
NCT01107522 | Phase I | Carboxyamidotriazole Orotate + Temozolomide Carboxyamidotriazole Orotate | Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas | Unknown status | USA | 0 |
NCT01130077 | Phase I | Poly ICLC | A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction With Poly-ICLC in Pediatric Gliomas | Active, not recruiting | USA | 0 |
NCT01156584 | Phase I | Toca 511 + Toca FC | A Study of a Retroviral Replicating Vector Administered to Subjects With Recurrent Malignant Glioma | Completed | USA | 0 |
NCT01188096 | Phase II | Poly ICLC | A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas | Completed | USA | 0 |
NCT01266031 | Phase Ib/II | Bevacizumab + Vorinostat Bevacizumab | Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma | Completed | USA | 0 |
NCT01331135 | Phase I | Sirolimus | Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors | Completed | USA | 0 |
NCT01386580 | Phase Ib/II | 2B3-101 2B3-101 + Trastuzumab | An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma. | Completed | USA | FRA | BEL | 1 |
NCT01392209 | Phase I | Bevacizumab | Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma | Completed | USA | 0 |
NCT01434602 | Phase Ib/II | Everolimus + Sorafenib | Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas | Completed | USA | 0 |
NCT01435395 | Phase I | Bevacizumab + Bortezomib + Temozolomide | Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme | Completed | USA | 0 |
NCT01478178 | Phase Ib/II | VAL-083 | Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma or Progressive Secondary Brain Tumor | Completed | USA | 0 |
NCT01478321 | Phase II | Bevacizumab + Temozolomide | Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas | Terminated | USA | 0 |
NCT01547546 | Phase I | GDC-0084 | A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma | Completed | USA | ESP | 0 |
NCT01644773 | Phase I | Crizotinib + Dasatinib | Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG) | Completed | USA | 0 |
NCT01648348 | Phase Ib/II | Carotuximab Bevacizumab | Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme | Completed | USA | 0 |
NCT01661400 | Phase I | Cyclophosphamide Thalidomide | Anti-Angiogenic Therapy Post Transplant (ASCR) for Relapsed and Refractory Pediatric Solid Tumors | Active, not recruiting | USA | 0 |
NCT01677741 | Phase I | Dabrafenib | A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects | Completed | USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 2 |
NCT01743950 | Phase II | Bevacizumab | A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab | Recruiting | USA | 0 |
NCT01748149 | Phase I | Vemurafenib | Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas | Active, not recruiting | USA | CAN | 0 |
NCT01817751 | Phase II | Valproic acid Sorafenib | Sorafenib Tosylate, Valproic Acid, and Sildenafil Citrate in Treating Patients With Recurrent High-Grade Glioma | Active, not recruiting | USA | 0 |
NCT01903330 | Phase II | Bevacizumab Cyclophosphamide Sargramostim | ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme | Active, not recruiting | USA | 0 |
NCT01925573 | Phase I | Bevacizumab | NOVOTTF-100A+ Bevacizumab+ Hypofractionated Stereotactic Irradiation Bevacizumab-Naive Recurrent Glioblastoma (GCC 1344) | Terminated | USA | 0 |
NCT01954030 | Phase Ib/II | Bevacizumab Carboxyamidotriazole Orotate | Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure | Terminated | USA | 0 |
NCT01977677 | Phase Ib/II | Temozolomide Plerixafor | Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma | Completed | USA | 0 |
NCT01985256 | Phase I | Toca 511 | Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor | Completed | USA | 0 |
NCT01989052 | Phase Ib/II | Lomustine Carboxyamidotriazole Orotate | Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma | Terminated | USA | 0 |
NCT02017717 | Phase III | Nivolumab Bevacizumab Ipilimumab + Nivolumab | A Randomized Study of Nivolumab Versus Bevacizumab and a Safety Study of Nivolumab in Adult Subjects With Recurrent Glioblastoma (GBM) (CheckMate 143) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | BEL | AUS | 4 |
NCT02023905 | Phase II | Temozolomide Everolimus | Everolimus With and Without Temozolomide in Adult Low Grade Glioma | Terminated | USA | 0 |
NCT02026271 | Phase I | Ad-RTS-IL-12 plus AL | A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma | Completed | USA | 0 |
NCT02034110 | Phase II | Dabrafenib + Trametinib | Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers | Completed | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | 6 |
NCT02052648 | Phase Ib/II | Temozolomide Indoximod | Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors | Completed | USA | 0 |
NCT02100891 | Phase II | Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors | Active, not recruiting | USA | 0 | |
NCT02101905 | Phase I | Lapatinib | Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma | Active, not recruiting | USA | 0 |
NCT02186509 | Phase I | Alisertib | Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas | Completed | USA | 0 |
NCT02193347 | Phase I | Montanide ISA 51 + PEPIDH1M vaccine + Sargramostim + Temozolomide | IDH1 Peptide Vaccine for Recurrent Grade II Glioma (RESIST) | Unknown status | USA | 0 |
NCT02238496 | Phase II | Perifosine + Temsirolimus | Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas | Completed | USA | 0 |
NCT02273739 | Phase Ib/II | Enasidenib | Study of Orally Administered AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation | Completed | USA | FRA | 0 |
NCT02303678 | Phase I | D2C7-IT | D2C7 for Adult Patients With Recurrent Malignant Glioma | Active, not recruiting | USA | 0 |
NCT02311582 | Phase Ib/II | Pembrolizumab | MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas | Active, not recruiting | USA | 0 |
NCT02313272 | Phase I | Bevacizumab + Pembrolizumab | Phase I Trial of HFSRT With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas | Completed | USA | 0 |
NCT02323880 | Phase I | Selinexor | Study of Selinexor in Pediatric Solid Tumors | Active, not recruiting | USA | 0 |
NCT02330562 | Phase I | Bevacizumab + Marizomib | Study of Marizomib With Bevacizumab in Bevacizumab-Naïve Subjects With WHO Grade IV Malignant Glioma | Completed | USA | CAN | 0 |
NCT02332889 | Phase Ib/II | Decitabine Poly ICLC | Phase I/II Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs | Terminated | USA | 0 |
NCT02337491 | Phase II | Pembrolizumab Bevacizumab + Pembrolizumab | Pembrolizumab +/- Bevacizumab for Recurrent GBM | Completed | USA | 0 |
NCT02337686 | Phase II | Pembrolizumab | Pharmacodynamic Study of Pembrolizumab in Patients With Recurrent Glioblastoma | Active, not recruiting | USA | 0 |
NCT02343718 | Phase I | Temsirolimus + Vinblastine | Vinblastine and Temsirolimus in Pediatric Patients With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours | Completed | CAN | 0 |
NCT02345824 | Phase I | Ribociclib | Early-Phase Study to Assess Inhibitor LEE011 in Patients With Recurrent Glioblastoma or Anaplastic Glioma | Unknown status | USA | 0 |
NCT02358187 | Phase II | Poly ICLC | A Vaccine Trial for Low Grade Gliomas | Recruiting | USA | 0 |
NCT02359565 | Phase I | Pembrolizumab | Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas or Diffuse Intrinsic Pontine Gliomas | Recruiting | USA | CAN | 0 |
NCT02366728 | Phase II | pp65 Dendritic Cell Vaccine + Temozolomide | C Migration Study for Newly-Diagnosed GBM (ELEVATE) | Completed | USA | 0 |
NCT02372006 | Phase Ib/II | Afatinib | Trial of Afatinib in Pediatric Tumours | Completed | USA | ITA | GBR | FRA | ESP | DEU | CAN | AUT | AUS | 3 |
NCT02390752 | Phase Ib/II | Pexidartinib | PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) | Recruiting | USA | 0 |
NCT02423343 | Phase Ib/II | Galunisertib Nivolumab | A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, Hepatocellular Carcinoma, or Glioma | Completed | USA | ESP | 0 |
NCT02423525 | Phase I | Afatinib | Safety Study of Afatinib for Brain Cancer | Completed | USA | 0 |
NCT02428712 | Phase Ib/II | PLX8394 | A Study of FORE8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors | Active, not recruiting | USA | 0 |
NCT02455245 | Phase III | Carboplatin Carboplatin + Vincristine Sulfate | A Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults With Previously Untreated Low Grade Glioma | Unknown status | USA | 0 |
NCT02481154 | Phase I | AG-881 | Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation | Active, not recruiting | USA | 0 |
NCT02490800 | Phase Ib/II | BAL101553 | Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors or Glioblastoma or High-grade Glioma | Completed | GBR | DEU | BEL | 1 |
NCT02502708 | Phase I | Indoximod Temozolomide | Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Primary Malignant Brain Tumors | Completed | USA | 0 |
NCT02507583 | Phase I | IGF-1R/AS ODN | Antisense102: Pilot Immunotherapy for Newly Diagnosed Malignant Glioma | Completed | USA | 0 |
NCT02525692 | Phase II | ONC201 | Oral ONC201 in Recurrent GBM, H3 K27M Glioma, and Midline Glioma | Active, not recruiting | USA | 0 |
NCT02529072 | Phase I | Nivolumab | Nivolumab With DC Vaccines for Recurrent Brain Tumors | Completed | USA | 0 |
NCT02540161 | Phase II | SYM004 | Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma | Completed | USA | 0 |
NCT02549833 | Phase I | GBM6-AD lysate protein vaccine + Poly ICLC | Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma | Active, not recruiting | USA | 0 |
NCT02607124 | Phase Ib/II | Ribociclib | Administration of Ribociclib Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG) | Terminated | USA | 0 |
NCT02639546 | Phase Ib/II | Cobimetinib | Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors (iMATRIXcobi) | Completed | USA | ITA | GBR | FRA | ESP | DEU | 1 |
NCT02644291 | Phase I | Mebendazole | Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors | Completed | USA | 0 |
NCT02644460 | Phase I | Abemaciclib | Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors | Recruiting | USA | 0 |
NCT02655601 | Phase Ib/II | BMX-001 + Temozolomide Temozolomide | Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001 | Active, not recruiting | USA | 0 |
NCT02658279 | Phase I | Pembrolizumab | Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype | Active, not recruiting | USA | 0 |
NCT02659800 | Phase I | Dexamethasone + NT-I7 Dexamethasone | Study of the Effect IL 7/ NT-I7 on CD4 Counts in Patients With High Grade Gliomas | Active, not recruiting | USA | 0 |
NCT02661282 | Phase Ib/II | Autologous CMV-specific CTLs + Temozolomide | Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma | Completed | USA | 0 |
NCT02669173 | Phase I | Bevacizumab + Capecitabine | Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma | Active, not recruiting | USA | 0 |
NCT02684058 | Phase II | Dabrafenib + Trametinib | Phase II Pediatric Study With Dabrafenib in Combination With Trametinib in Patients With HGG | Completed | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 11 |
NCT02743078 | Phase II | Bevacizumab | Optune Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma | Terminated | USA | 0 |
NCT02768389 | Phase I | Bevacizumab | Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma | Completed | USA | 0 |
NCT02794883 | Phase II | Tremelimumab Durvalumab + Tremelimumab Durvalumab | Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma | Completed | USA | 0 |
NCT02829931 | Phase I | Nivolumab | Hypofractionated Stereotactic Irradiation With Nivolumab in Patients With Recurrent High Grade Gliomas | Completed | USA | 0 |
NCT02833701 | Phase I | Bevacizumab | Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma | Terminated | USA | 0 |
NCT02840409 | Phase II | Vinblastine Bevacizumab + Vinblastine | Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG) | Recruiting | USA | CAN | AUS | 1 |
NCT02852655 | Phase 0 | Pembrolizumab | A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma | Completed | USA | 0 |
NCT02859857 | Phase I | BXQ-350 | Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT02871843 | Phase I | RRx-001 + Temozolomide | Phase 1 Two Part Dose Escalation Trial of RRx-001 + Radiation + Temozolomide and RRx-001 + Temozolomide Post-RT In Newly Diagnosed Glioblastoma and Anaplastic Gliomas (G-FORCE-1) | Completed | USA | 0 |
NCT02885324 | Phase II | Cabozantinib | Pilot Study of Cabozantinib for Recurrent or Progressive High-Grade Glioma in Children | Terminated | USA | 0 |
NCT02924038 | Phase I | IMA950 + Poly ICLC Varlilumab | A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG) | Active, not recruiting | USA | 0 |
NCT02933736 | Phase 0 | Ribociclib | Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients | Active, not recruiting | USA | 0 |
NCT02960230 | Phase Ib/II | H3.3K27M peptide vaccine + Montanide ISA 51 + Nivolumab + Poly ICLC + Tetanus Toxoid peptide H3.3K27M peptide vaccine + Montanide ISA 51 + Poly ICLC + Tetanus Toxoid peptide | H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas | Active, not recruiting | USA | 1 |
NCT02968940 | Phase II | Avelumab | Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma | Completed | USA | 0 |
NCT02977689 | Phase II | IDH305 | Trial of IDH305 in IDH1 Mutant Grade II or III Glioma | Withdrawn | USA | 0 |
NCT02986178 | Phase II | Lomustine + PVSRIPO PVSRIPO | PVSRIPO With/Without Lomustine | Active, not recruiting | USA | 0 |
NCT03072134 | Phase I | NSC-CRAd-Survivin-pk7 | Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma | Completed | USA | 0 |
NCT03095248 | Phase II | Selumetinib | Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors (SEL-TH-1601) | Recruiting | USA | 0 |
NCT03130959 | Phase II | Ipilimumab + Nivolumab Nivolumab | An Investigational Immuno-therapy Study of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Patients With High Grade Primary CNS Malignancies (CheckMate 908) | Completed | USA | GBR | FRA | ESP | DEU | CAN | AUS | 8 |
NCT03134131 | Expanded access | ONC201 | Expanded Access Program for ONC201 to Treat Recurrent Histone H3 Mutant Glioma | No longer available | USA | 0 |
NCT03173950 | Phase II | Nivolumab | Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS Cancers | Recruiting | USA | 0 |
NCT03174197 | Phase Ib/II | Atezolizumab + Temozolomide | Atezolizumab (aPDL1) + Temozolomide and Radiation for Newly Diagnosed Glioblastoma (GBM) | Active, not recruiting | USA | 0 |
NCT03210714 | Phase II | Erdafitinib | Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) | Active, not recruiting | USA | 1 |
NCT03212274 | Phase II | Olaparib | Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations | Recruiting | USA | 0 |
NCT03213678 | Phase II | LY3023414 | Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) | Active, not recruiting | USA | 1 |
NCT03220646 | Phase II | Abemaciclib | Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors | Active, not recruiting | USA | 0 |
NCT03233204 | Phase II | Olaparib | Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) | Active, not recruiting | USA | 1 |
NCT03245151 | Phase Ib/II | Everolimus + Lenvatinib | Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors | Completed | USA | CAN | 0 |
NCT03283631 | Phase I | EGFR-vIII CAR-T Cells | Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM | Terminated | USA | 0 |
NCT03295396 | Phase II | ONC201 | ONC201 in Adults With Recurrent H3 K27M-mutant Glioma | Active, not recruiting | USA | 0 |
NCT03352427 | Phase II | Dasatinib + Everolimus | Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring PDGFR Alterations | Terminated | USA | 0 |
NCT03355794 | Phase I | Everolimus + Ribociclib | A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG) | Completed | USA | 0 |
NCT03387020 | Phase I | Ribociclib Everolimus + Ribociclib | Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors | Completed | USA | 0 |
NCT03389230 | Phase I | HER2 CAR-T cells | Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma | Recruiting | USA | 0 |
NCT03416530 | Phase I | ONC201 | ONC201 in Pediatric H3 K27M Gliomas | Active, not recruiting | USA | 0 |
NCT03426891 | Phase I | Pembrolizumab + Temozolomide + Vorinostat | Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma | Active, not recruiting | USA | 0 |
NCT03452930 | Phase I | Tinostamustine | Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma | Active, not recruiting | USA | 0 |
NCT03463265 | Phase II | Lomustine + Nab-rapamycin Nab-rapamycin Nab-rapamycin + Temozolomide Bevacizumab + Nab-rapamycin | ABI-009 (Nab-Rapamycin) in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma | Completed | USA | 0 |
NCT03514069 | Phase I | Ruxolitinib Ruxolitinib + Temozolomide | Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma | Active, not recruiting | USA | 0 |
NCT03557359 | Phase II | Nivolumab | Nivolumab for Recurrent or Progressive IDH Mutant Gliomas | Active, not recruiting | USA | 0 |
NCT03581292 | Phase II | Temozolomide + Veliparib Veliparib | Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations | Active, not recruiting | USA | CAN | AUS | 2 |
NCT03598244 | Phase I | Savolitinib | Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors | Recruiting | USA | 0 |
NCT03605550 | Phase I | PTC596 | A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma | Recruiting | USA | 0 |
NCT03632317 | Phase II | Everolimus + Panobinostat | A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas | Withdrawn | USA | 0 |
NCT03652545 | Phase I | MultiTAA-specific T cells | Multi-antigen T Cell Infusion Against Neuro-oncologic Disease (REMIND) | Recruiting | USA | 0 |
NCT03684811 | Phase Ib/II | Cisplatin + Gemcitabine + Olutasidenib Azacitidine + Olutasidenib Olutasidenib Nivolumab + Olutasidenib | A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation | Completed | USA | GBR | FRA | ESP | AUS | 1 |
NCT03687957 | Phase Ib/II | Radiotherapy + Temozolomide NT-I7 + Radiotherapy + Temozolomide | rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-lymphopenic Gliomas Following Radiation and Temzolomide | Recruiting | USA | 0 |
NCT03690869 | Phase Ib/II | Cemiplimab | REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma | Recruiting | USA | 0 |
NCT03696355 | Phase I | GDC-0084 | Study of GDC-0084 in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline Gliomas | Completed | USA | 0 |
NCT03698994 | Phase II | Ulixertinib | Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) | Active, not recruiting | USA | 1 |
NCT03718767 | Phase II | Nivolumab | Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype | Recruiting | USA | 0 |
NCT03746080 | Phase II | Plerixafor + Temozolomide | Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma | Recruiting | USA | 0 |
NCT03749187 | Phase I | Pamiparib + Temozolomide | BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas (PNOC017) | Recruiting | USA | 0 |
NCT03763396 | Phase I | Posaconazole Ketoconazole | Azoles Targeting Recurrent High Grade Gliomas | Unknown status | CAN | 0 |
NCT03834740 | Phase I | Everolimus + Ribociclib | A Phase 0 /II Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection | Completed | USA | 0 |
NCT03838042 | Phase Ib/II | Entinostat + Nivolumab | INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies (INFORM2 NivEnt) | Recruiting | FRA | DEU | AUT | AUS | 3 |
NCT03893487 | Phase I | CUDC-907 | Fimepinostat in Treating Brain Tumors in Children and Young Adults (PNOC016) | Active, not recruiting | USA | 1 |
NCT03893903 | Phase I | Avelumab IDH1 R132H peptide vaccine Avelumab + IDH1 R132H peptide vaccine | AMPLIFYing NEOepitope-specific VACcine Responses in Progressive Diffuse Glioma (AMPLIFY-NEOVAC) | Recruiting | DEU | 0 |
NCT03914742 | Phase Ib/II | Pamiparib + Temozolomide | BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations | Active, not recruiting | USA | 0 |
NCT03919071 | Phase II | Dabrafenib + Trametinib | Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma | Recruiting | USA | 1 |
NCT03922555 | Phase I | Decitabine and Cedazuridine | ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas | Recruiting | USA | 0 |
NCT03973879 | Phase Ib/II | Atezolizumab + PVSRIPO | Combination of PVSRIPO and Atezolizumab for Adults With Recurrent Malignant Glioma | Withdrawn | 0 | |
NCT03973918 | Phase II | Binimetinib + Encorafenib | Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG (BRAF) | Active, not recruiting | USA | 0 |
NCT04015700 | Phase I | GNOS-PV01 + INO-9012 | Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma | Active, not recruiting | USA | 0 |
NCT04047706 | Phase I | Linrodostat + Nivolumab Linrodostat + Nivolumab + Temozolomide | Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma | Active, not recruiting | USA | 0 |
NCT04051606 | Phase II | Regorafenib | Phase II Study of Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma | Active, not recruiting | USA | 0 |
NCT04089449 | Phase I | PRT811 | A Study of PRT811 in Participants With Advanced Solid Tumors, Gliomas and Myelofibrosis | Completed | USA | 0 |
NCT04099797 | Phase I | C7R-GD2.CART cells Cyclophosphamide + Fludarabine | C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B) | Recruiting | USA | 0 |
NCT04160494 | Phase I | Atezolizumab + D2C7-IT | D2C7-IT With Atezolizumab for Recurrent Gliomas | Active, not recruiting | USA | 0 |
NCT04166409 | Phase III | Selumetinib Carboplatin + Vincristine Sulfate | A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma | Recruiting | USA | CAN | 1 |
NCT04172597 | Phase II | Poziotinib | A Study of Poziotinib in Patients With EGFR or HER2 Activating Mutations in Advanced Malignancies | Terminated | USA | 0 |
NCT04195139 | Phase II | Nivolumab + Temozolomide Temozolomide | Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM (NUTMEG) | Active, not recruiting | USA | AUS | 0 |
NCT04201457 | Phase Ib/II | Hydroxychloroquine + Trametinib Dabrafenib + Hydroxychloroquine + Trametinib | A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration | Recruiting | USA | 0 |
NCT04214392 | Phase I | Chlorotoxin-CD28-CD3z-CD19t CART cells | Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MPP2+ Recurrent or Progressive Glioblastoma | Recruiting | USA | 0 |
NCT04220892 | Phase I | Abemaciclib + Pembrolizumab Pembrolizumab + Pemetrexed Disodium | Pilot Study of Pembrolizumab Combined With Pemetrexed or Abemaciclib for High Grade Glioma | Withdrawn | USA | 0 |
NCT04254419 | Phase I | Intra-tumoral Injection of Natural Killer Cells in High-Grade Gliomas | Not yet recruiting | USA | 0 | |
NCT04267146 | Phase Ib/II | Nivolumab + Temozolomide | Nivolumab in Combination With Temozolomide and Radiotherapy in Children and Adolescents With Newly Diagnosed High-grade Glioma (NIVOGLIO) | Recruiting | FRA | 0 |
NCT04295759 | Phase I | INCB7839 | INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas | Active, not recruiting | USA | 0 |
NCT04323046 | Phase I | Ipilimumab Ipilimumab + Nivolumab Nivolumab | Immunotherapy (Nivolumab and Ipilimumab) Before and After Surgery for the Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults | Active, not recruiting | USA | AUS | 2 |
NCT04334863 | Phase I | WP1066 | AflacST1901: Peds WP1066 | Completed | USA | 0 |
NCT04391595 | Phase I | Abemaciclib + LY3214996 | LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients | Recruiting | USA | 0 |
NCT04424966 | Phase 0 | Infigratinib | Infigratinib in Recurrent High-Grade Glioma Patients | Terminated | USA | 0 |
NCT04465643 | Phase I | Ipilimumab + Nivolumab | Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor | Recruiting | USA | 0 |
NCT04482933 | Phase II | HSV-1 G207 | HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma | Not yet recruiting | USA | 0 |
NCT04485559 | Phase I | Everolimus + Trametinib | Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021) | Recruiting | USA | 0 |
NCT04521686 | Phase I | LY3410738 | Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations | Active, not recruiting | USA | FRA | ESP | AUS | 5 |
NCT04541082 | Phase I | ONC206 | Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms | Recruiting | USA | 0 |
NCT04541225 | Phase Ib/II | NUV-422 | Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas | Terminated | USA | 0 |
NCT04547777 | Phase I | 2141 V-11 + D2C7-IT | Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma | Recruiting | USA | 0 |
NCT04606316 | Phase I | Nivolumab Ipilimumab + Nivolumab | Surgical Nivolumab And Ipilimumab For Recurrent GBM | Recruiting | USA | 0 |
NCT04608812 | Phase I | OS2966 | Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a Surgical Resection | Active, not recruiting | USA | 0 |
NCT04655404 | Phase I | Larotrectinib | A Pilot Study of Larotectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion (CONNECT1903) | Recruiting | USA | GBR | DEU | CAN | AUS | 1 |
NCT04656535 | Phase I | Zimberelimab AB154 AB154 + Zimberelimab | AB154 Combined With AB122 for Recurrent Glioblastoma | Recruiting | USA | 0 |
NCT04691960 | Phase II | Metformin | A Pilot Study of Ketogenic Diet and Metformin in Glioblastoma: Feasibility and Metabolic Imaging | Recruiting | USA | 0 |
NCT04732065 | Phase I | ONC206 | ONC206 for Treatment of Newly Diagnosed or Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant Brain Tumors (PNOC 023) | Recruiting | USA | 1 |
NCT04771897 | Phase I | BXQ-350 | A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) or Diffuse Midline Glioma (DMG) (KONQUER) | Recruiting | USA | 0 |
NCT04773782 | Phase Ib/II | Avapritinib | A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling | Recruiting | USA | ITA | FRA | DEU | CAN | AUT | AUS | 1 |
NCT04826393 | Phase I | ASP8374 + Cemiplimab | ASP8374 + Cemiplimab in Recurrent Glioma | Active, not recruiting | USA | 0 |
NCT04851834 | Phase Ib/II | Cisplatin + NTX-301 NTX-301 NTX-301 + Temozolomide Carboplatin + NTX-301 | NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma | Terminated | AUS | 0 |
NCT04903795 | Phase I | hEGFRvIII-CD3 bi-scFv | Bispecific T Cell Engager BRiTE for Patients With Grade IV Malignant Glioma (BRiTE) | Not yet recruiting | USA | 0 |
NCT05009992 | Phase II | GDC-0084 + ONC201 ONC201 + Panobinostat | Combination Therapy for the Treatment of Diffuse Midline Gliomas | Recruiting | USA | AUS | 4 |
NCT05023551 | Phase I | DSP-0390 | Study of DSP-0390 in Patients With Recurrent High-Grade Glioma | Recruiting | USA | 1 |
NCT05076513 | Phase I | Niraparib | Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma | Recruiting | USA | 0 |
NCT05084430 | Phase Ib/II | M032 + Pembrolizumab | Study of Pembrolizumab and M032 (NSC 733972) | Recruiting | USA | 0 |
NCT05099003 | Phase Ib/II | Selinexor | A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG) | Recruiting | USA | CAN | 0 |
NCT05135975 | Phase II | Cabozantinib | A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors | Recruiting | USA | 0 |
NCT05188508 | Phase II | Olaparib + Pembrolizumab + Temozolomide | Pembrolizumab, Olaparib, and Temozolomide for People With Glioma | Recruiting | USA | 0 |
NCT05283109 | Phase I | P30-EPS + Poly ICLC | ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM (ETAPA I) | Not yet recruiting | USA | 0 |
NCT05297864 | Phase II | Niraparib | PARP Inhibition for Gliomas (PI-4G or pi4g) | Recruiting | USA | 0 |
NCT05345002 | Phase II | Retifanlimab + Tretinoin | All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma | Recruiting | USA | 0 |
NCT05388435 | Phase Ib/II | SKL27969 | Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients | Recruiting | USA | 0 |
NCT05394558 | Phase Ib/II | AsiDNA | AsiDNA Children, Adolescents and Young Adults (AsiDNA) | Recruiting | FRA | 0 |
NCT05406700 | Phase I | Niraparib | Niraparib In Recurrent IDH 1/2 Gliomas | Recruiting | USA | 0 |
NCT05413304 | Phase I | Abemaciclib + Temozolomide Abemaciclib | Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral Microdialysis | Recruiting | USA | 0 |
NCT05417594 | Phase Ib/II | AZD9574 AZD9574 + Temozolomide | Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies (CERTIS1) | Recruiting | USA | GBR | ESP | DEU | AUS | 2 |
NCT05429502 | Phase Ib/II | Ribociclib + Temozolomide + Topotecan | Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors | Recruiting | USA | FRA | ESP | DEU | 1 |
NCT05463848 | Phase II | Olaparib + Pembrolizumab + Temozolomide Pembrolizumab | Surgical Pembro +/- Olaparib w TMZ for rGBM | Recruiting | USA | 0 |
NCT05500508 | Phase Ib/II | AMXT1501 + Eflornithine | Oral AMXT 1501 Dicaprate in Combination With IV DFMO | Recruiting | USA | 0 |
NCT05588141 | Phase Ib/II | Zotiraciclib | Study of Zotiraciclib for Recurrent High-Grade Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations | Recruiting | USA | 0 |
NCT05609994 | Phase I | AG-881 + PEPIDH1M vaccine | ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas (ViCToRy) | Not yet recruiting | USA | 0 |
NCT05610891 | Phase I | CLR 131 | Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG | Not yet recruiting | USA | 0 |
NCT05743595 | Phase I | Personalized cancer vaccine + Retifanlimab | Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma | Not yet recruiting | USA | 0 |
NCT05773326 | Phase I | Temsirolimus | Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG | Recruiting | USA | 0 |
NCT05804227 | Phase I | Ulixertinib | Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Low-Grade Gliomas in Adults | Recruiting | USA | 0 |
NCT05843253 | Phase II | Everolimus + Ribociclib | Study of Ribociclib and Everolimus in HGG and DIPG | Not yet recruiting | USA | GBR | DEU | CAN | AUS | 1 |